Stay updated with breaking news from Lars Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Monitoring metal ion concentrations and chelation therapy is hypothesized to alleviate symptoms and diseases caused by neuroinflammation.
Does your blood type play a role in your risk for disease? Find out how it fares in the face of certain conditions.
Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.